Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shorter immunotherapy course may be enough for some breast cancer patients — a major trial puts it to the test

NCT ID NCT06606730

Recruiting now Disease control Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether patients with early-stage triple-negative breast cancer who have a complete response to standard chemotherapy plus the immunotherapy drug pembrolizumab can safely stop pembrolizumab early instead of continuing it for an additional six months. The study enrolls around 2,450 participants and compares recurrence-free survival between those who stop and those who continue treatment. The goal is to see if a shorter course can reduce side effects and improve quality of life without compromising cancer control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pembrolizumab (Keytruda), an immunotherapy drug
What this could lead to
If successful, this could show that some patients with triple-negative breast cancer can safely stop immunotherapy early after a complete response, reducing treatment burden and side effects without raising the risk of recurrence.
What could go wrong
This is a phase 3 trial, but it tests a non-inferiority question — meaning it aims to prove that stopping treatment is not worse than continuing. If the results are inconclusive or show a slightly higher recurrence risk, the approach may not be adopted. Side effects of pembrolizumab, such as immune-related inflammation, remain a concern.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCERS TRIPLE NEGATIVE BREAST CANCER (TNBC)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cliniques Universitaires Saint Luc Brussels

    RECRUITING

    Brussels, 1200, Belgium

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Institut Gustave Roussy

    RECRUITING

    Villejuif, 94805, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.